Lacosamide vs. Controlled-Release Carbamazepine Monotherapy as Initial Epilepsy Treatment

Lacosamide was no less effective for new-onset seizures in patients with clinically suspected partial epilepsy.

Nearly all new antiepilepsy medications (AEDs) obtain initial indications as adjunctive (add-on) therapy in patients with medically uncontrolled epilepsy, yet most patients are treated (or wish to be) with only one medicine. Very few head-to-head comparisons have been done between new AEDs and older medications with established efficacy in the largest generalizable populations: those with new-onset seizures or those that can be controlled with one AED. Lacosamide (LCM) is FDA-approved as monotherapy based on historical controls and is not approved as monotherapy in Europe. This large international, double-blind, randomized, manufacturer-sponsored study compared efficacy and adverse effects of LCM versus controlled-release carbamazepine (CBZ…

Reviewing Author

Robert C. Knowlton, MD, MSPH

Disclosures

Consultant/Advisory BoardMore Health, Inc.; The Alliance of Medical Companies

Grant/Research SupportNIH Small Business Innovation Research

Leadership Positions in Professional SocietiesSouthern Epilepsy & EEG Society (Treasurer)

Robert C. Knowlton, MD, MSPH

Disclosures

Consultant/Advisory BoardMore Health, Inc.; The Alliance of Medical Companies

Grant/Research SupportNIH Small Business Innovation Research

Leadership Positions in Professional SocietiesSouthern Epilepsy & EEG Society (Treasurer)

Lacosamide vs. Controlled-Release Carbamazepine Monotherapy as Initial Epilepsy Treatment

Topics

Reviewing Author